Company: PTHS
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001753926-25-001326
Chunk: 105

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 8
Chunk 105
---
 —

    $
    —

    Granted

    —

    —

    Vested

    —

    —

    Forfeited

    —

    —

    Non-vested at June 30, 2025

    —

    $
    —

    Non-vested
    Warrants
     
    Warrants

    Weighted-
    Average
    Exercise
    Price

    Non-vested at December 31,
    2023

    —

    $
    —

    Granted

    5,500

    75.00

    Vested

    (5,500
    )

    75.00

    Forfeited

    —

    —

    Non-vested at June 30, 2024

    —

    $
    —

The
total number of warrants granted during the three months ended June 30, 2025 and 2024 was 0 and 0,
respectively. The total number of warrants granted during the six months ended June 30, 2025 and 2024 was 0 and 5,500,
respectively. The exercise price for these warrants was $75.00 per share and there was an intrinsic value of $0.

The
Company recognized stock-based compensation expense related to warrant vesting amortization of $0 and $0 for the three and six
months ended June 30, 2025 and 2024, respectively.

RSUs

A
summary of the status of the Company’s nonvested RSUs as of June 30, 2024, and changes during the three and six months ended
June 30, 2024, is presented below:

    Non-vested
    RSUs
     
    RSUs

    Weighted-
    Average
    Exercise
    Price

    Non-vested at December 31,
    2023

    —

    $
    —

    Granted

    25,710

    $
    13.00

    Vested

    —

    $
    —

    Forfeited

    —

    $
    —

    Non-vested at
    June 30, 2024

    25,710

    $
    13.00

A
summary of the status of the Company’s nonvested RSUs as of June 30, 2025, and changes during the three and six months ended
June 30, 2025, is presented below: